Objective: To investigate utility of a Multiple Sclerosis Severity Scale (MSSS)-based classification system for comparing African American (AA) and white American (WA) multiple sclerosis (MS) subpopulations in the New York State Multiple Sclerosis Consortium (NYSMSC) database. MSSS is a frequency-rank algorithm relating MS disability to disease duration in a large, untreated reference population.
On the other hand, analysis of Expanded Disability Status Scale (EDSS) disability scores among AA and WA patients in the New York State Multiple Sclerosis Consortium (NYSMSC) database 14 failed to show that race was a predictor of EDSS. However, disease duration positively modified the relation between race and EDSS, implying that as disease duration increased, AA were more likely to have higher EDSS. 19 Given these suggestive results, we sought to compare disability in the AA and WA subpopulations in an updated and expanded NYSMSC dataset with a novel and more nuanced tool for assessment of disease progression: Multiple Sclerosis Severity Score (MSSS)-based classification.
METHODS The NYSMSC database contains patientreported and physician-reported data from 19 MS centers throughout New York state. Patients who listed their ethnicity as black/AA or non-Hispanic white (WA) were eligible for analysis. The categories for racial self-identification were the same as in the US Census Bureau (2000) . We analyzed data from all patients in the database for whom EDSS was recorded 1-30 years from symptom onset. If more than one EDSS score was available for a patient, the first recorded value was used to calculate MSSS. Patients without an EDSS during years 1-30 from symptom onset were excluded from analysis.
Global MSSS, which is derived from the analysis of EDSS distributions of nearly 10,000 untreated patients enrolled in 17 European MS centers, represents a median decile rank of each EDSS grade in a population of patients with similar disease durations. 20 MSSS is an indicator of the relative rate of disability progression, rather than of disability per se, and is therefore a more suitable measure for comparing disease trajectories in different MS populations than EDSS. MSSS may be used to compare disease progression in a local MS patient population to the reference untreated European MS population from which the original Global MSSS Table has been derived, or to compare subpopulations of interest within the local population. Population comparison is made simpler with a 6-tiered stratification, proposed by Herbert, 21 in which the decile MSSS scale is divided into 6 severity grades, each containing one-sixth (16.7%) of the reference population. For example, grade 1 contains all patients with MSSS Յ1.67, and thus comprises 16.7% of the slowest progressors, the subset of patients in the reference population whose EDSS scores are lower than those of 83.3% of patients of the reference population with similar disease duration. Conversely, grade 6 contains all patients with MSSS Ն8.33, or 16.7% of the fastest progressors, whose EDSS scores are higher than those of 83.3% of patients with the same disease duration. The intermediate grades were defined as follows: grade 2, MSSS between 1.67 and 3.33; grade 3, 3.33 Ͻ MSSS Յ 5.00; grade 4, 5.00 Ͻ MSSS Յ 6.67; grade 5, 6.67 Ͻ MSSS Յ 8.33.
MSSS can also be used to stringently define benign MS and malignant MS. Cutoff for benign MS was chosen to be MSSS Ͻ0.45, which corresponds to EDSS of 3.5 or less after 30 years of disease. 22, 23 Similarly, malignant MS was defined as any pa-tient with MSSS Ն9.6, which corresponds to EDSS of 6.0 at 7 years. 24 MSSS scores were assigned unambiguously to any patient with EDSS from 0 to 9.5 and disease duration of 1-30 years by referencing the MSSS Table in Roxburgh et al. 20 Patients were then assigned to 1 of the 6 severity grades and into benign and malignant categories based on their MSSS scores.
For each of the 2 subsets of patients-AA and WA-the following characteristics were compared: age, gender, age at symptom onset, calendar year and disease duration at the time of EDSS examination, age at diagnosis, disease type, use of disease-modifying therapy (DMT), family history of MS, and history of coexisting autoimmune diseases. Univariate group comparisons were carried out using Mann-Whitney test for medians and percentiles, 2 test for proportions, and t test for time and age variables.
For multivariable analysis, 2 different approaches, ordinal logistic regression (proportional odds model) 25 and median regression, 26 were used to model MSSS in WA and AA while accounting for differences in relevant patient characteristics. Ordinal logistic regression was chosen because it yielded results that were a direct extension of univariate analysis of MSSS distribution across groups (i.e., a higher odds ratio in one group vs another group indicates an increased probability for members of the former group to be assigned to a higher MSSS grade compared to members of the latter group). Median regression analysis, used to estimate adjusted median MSSS for each patient group of interest, allows one to easily assess absolute differences in disease severity across groups. Thus, the 2 approaches complement and mutually reinforce each other.
All the patient characteristics examined in univariate analysis were accounted for in multivariable analyses. To accommodate for the possibility of nonlinear relationships of unknown shape between continuous covariates and outcomes of interest, age at symptom onset, disease duration, and year at the time of EDSS examination were modeled with restricted cubic splines (4 knots located at 5th, 35th, 65th, and 95th percentiles). Splines are smoothing functions used in regression analysis to assess trends and optimally control for bias due to continuous confounders. 27 Statistical analyses were performed using Stata software package, version 10. All p values are 2-tailed; p Ͻ 0.05 was considered significant.
RESULTS
As of September 2007, the NYSMSC dataset contained records on 499 patients who identified themselves as AA and 7,661 patients who identified themselves as non-Hispanic white (WA). Altogether, 419 AA (84% of total sample) and 5,819 WA patients (76%) fulfilled the inclusion criteria. Thus, the cohort of AA analyzed in this work includes 90 new patients compared to the previous analysis of AA in NYSMSC 14 -a 27% increase. Sensitivity analysis showed that there were no significant differences in characteristics of excluded and included patients.
Univariate analyses. Demographic and disease-related variables of AA and WA subsets are shown in table 1. The 2 groups were similar with respect to age at symptom onset, age at diagnosis, disease subtypes, use of disease-modifying therapies, presence of coexisting autoimmune disease, or of family history of MS. However, compared to WA, AA had higher female-to-male ratio (3.6:1 among AA and 2.6:1 among WA) and shorter time to first EDSS (mean of 7.7 years for AA and 10.3 for WA).
In agreement with the previous study of AA and WA in NYSMSC, which did not detect differences in EDSS between the racial groups, 14 median EDSS of the updated AA cohort was not significantly higher than in WA (3.5 vs 3.0, p ϭ 0.60).
In contrast to the EDSS, median MSSS of AA patients was higher than WA patients: 6.0 (interquartile range [IQR] 3.7-8.2) vs 4.8 (IQR 2.3-7.2; p Ͻ 0.0001). The breakdown of MSSS of AA and WA into severity grades as well as into the benign and malignant group is shown in figure 1. Compared to WA, AA patients were overrepresented in the 2 most severe grades (41.5% vs 29.3%) and underrepresented in the 2 least severe grades (27.4% vs 35.4%; overall p Ͻ 0.001). The most frequent MSSS grade in AA was grade 6 and in WA grade 2. The percentage of WA in the benign MS category (3.9%) was 1.6 times larger than AA in the same category (2.4%, p Ͻ 0.001), while prevalence of malignant MS was 2.6 times higher among AA (7.3%) compared to WA (2.9%; p Ͻ 0.001).
Median MSSS of the NYSMSC cohort-AA and WA patients combined-was 4.9 (IQR 2.4 -7.3), which closely approximates the median score of 5.0 among the European reference population. 20 Breakdown by grades within the NYSMSC was also very similar to the distribution in the European dataset: mean deviation from the expected value of 16.7% per grade was 1.3%, range Ϫ1.7% (14.9% in grade 5) to ϩ1.8% (18.4% in grade 2).
Multivariable ordinal logistic regression analysis. As shown in table 2, African ancestry was an independent and consistent predictor of worse MSSS among women for each age at disease onset and each disease type (ad- 
Figure 1 Distribution of African American (AA) and white American (WA) patients in 6 severity grades and benign and malignant categories
The dashed horizontal line across 6 grades represents the expected percentage of patients in each grade (16.7%). There is a significant trend for AA patients to be overrepresented in the most severe grades (5 and 6) and underrepresented in the least severe grades (1 and 2), while an inverse trend is seen with WA (p Ͻ 0.001). This trend is even more pronounced in the extremes of the spectrum: benign and malignant multiple sclerosis (MS) categories (p Ͻ 0.001). The expected percentage of patients in the benign grade is 4.5% (Multiple Sclerosis Severity Scale cutoff of 0.45) and in the malignant group 4% (Multiple Sclerosis Severity Scale cutoff of 9.6), but only 2.4% of AA were found to have benign MS, while 7.4% had malignant MS.
justed odds ratio ranging from 1.4 to 2.3 across all subsets of patients). Results for AA men were more equivocal, possibly owing to the small number of AA men in the dataset. Odds estimates for worse MSSS in AA men were typically higher than in WA of either gender, and lower than in AA women, but differences rarely reached statistical significance. WA men were moderately more likely to be in the higher severity grades as compared to WA women in the total sample and most subgroups (adjusted odds ratio 0.76 -1.6).
Multivariable median regression analysis. Adjusted median MSSS in the reference group-WA women-was 3.5 (95% confidence interval [CI] 3.2-3.9). Compared to this reference group, adjusted median MSSS in AA women was 1.5 points higher (95% CI 1.2-1.9; p Ͻ 0.001), in AA men 1.1 points higher (95% CI 0.3-1.8; p ϭ 0.004), and in WA men 0.7 point higher (95% CI 0.5-0.9; p Ͻ 0.001). Compared to WA women, adjusted median MSSS in the subgroup analyses by disease type and age at onset typically was 0.9 -1.6 points higher in AA women, 0.5-2.2 points higher in AA men, and 0.3-0.9 point higher in WA men ( figure 2) . Results of the stratified analyses should be interpreted with caution as differences among respective race and sex subgroups were not always consistent and significant. The 95% CIs for median estimates were often broad, partly owing to small number of AA men in some subsamples. Furthermore, it is possible that a ceiling effect masked differences across race and gender groups among patients with secondary progressive MS disease, as more than 50% of patients with this disease type were distributed in the 2 most severe MSSS grades.
DISCUSSION
The overall MSSS distribution in the NYSMSC dataset was very similar to that in the reference European untreated population, with deviation from the expected value (16.7%) of less than 1.8% for any of the 6 severity grades. However, the distribution of MSSS in the AA subset of the NYSMSC dataset was significantly right-shifted compared to that of their WA counterparts (and the reference European population)-median MSSS for AA was 6.0 compared to 4.8 in WA. The 1.2 difference in MSSS between the 2 groups implies that AA reach disability milestones more rapidly than WA. AA patients were significantly overrepresented in the malignant MS group, and in the 2 most severe grades (5 and 6), and underrepresented in the benign MS group and the 2 least severe grades (1 and 2) as compared to WA. Multivariable analysis showed that the differences in MSSS across racial lines persist after adjustment for age, disease duration, disease subtype, calendar year at the time of EDSS examination, use of DMT, family history of MS, and presence of coexisting autoimmune disease. Thus, the differences in disease severity do not appear to be due to the differences in baseline demographic characteristics or differential use of DMTs among the 2 groups. It should be noted, however, that because of the way data are recorded in the database, only treatment status at enrollment was available for multivariable analysis, not the duration of treatment. The differences were more obvious among AA women than men, possibly owing to the fact that there were almost 4 times more women than men in the AA subset. Abbreviations: CI ϭ confidence interval; OR ϭ odds ratio; PPMS ϭ primary-progressive multiple sclerosis; RRMS ϭ relapsing-remitting multiple sclerosis; SPMS ϭ secondaryprogressive multiple sclerosis. a All ORs are adjusted for disease duration, calendar year at the time of Expanded Disability Status Scale examination, use of disease-modifying therapy, family history of multiple sclerosis, and presence of coexisting autoimmune disease. Analyses in the total sample and analyses stratified by disease type (RRMS, PPMS, PPMS) are further adjusted for age at symptom onset. The reference group for each set of comparisons is WA women. The predictive accuracy of the model in the total sample to discriminate between patients classified in a higher vs a lower Multiple Sclerosis Severity Scale grade is C ϭ 0.82 (Harrell C statistic: predictive accuracy no better than chance alone: C ϭ 0.5; perfect predictive value: C ϭ 1.0 29 ).
It is instructive to compare our results with those of a recent study of MS in AA and WA that utilized MSSS as one of the outcome measures. 10 The mean MSSS of AA in that study was 1.1 points higher than in WA, which is nearly identical to the 1.2-point difference in MSSS between the 2 groups in our study. In addition, it is noteworthy that in the abovereferenced study AA were at 2-fold risk for requiring a cane to ambulate compared to WA, which is in excellent agreement with the odds ratio of 2 for assignment to a higher severity grade in our NYSMSC cohort (table  2) . It should be pointed out that our results on odds ratio are more general, as our analysis shows that AA are at 2-fold risk for reaching any disability milestone, not just use-of-cane milestone. One dissimilarity between the 2 studies is that both AA and WA patients in our study had slightly higher MSSS in both racial groups-a difference of 0.3-0.4 MSSS points. One possible explanation lies in the composition of the datasets: the NYSMSC cohort used in our study is a statewide registry of patients seen at established MS centers, while in the other study, 10 the cohort consisted of participants in a genetic study.
Since the MSSS is based in part on the EDSS, it has been suggested that it does not provide any obvious ad-vantage over the EDSS. The present study challenges that contention and demonstrates the utility of using an MSSS-based classification for comparing local subpopulations of interest. MSSS incorporates 2 factors which are not taken into account by raw EDSS scores: duration of disease and the expected change in EDSS over time. MSSS should therefore be considered as a measure of the relative rate of disability accumulation in MS, rather than of disability per se, and so provides complementary information to EDSS about patients' disease severity.
The divergence between the results of EDSS and MSSS analyses observed in our study is particularly noteworthy. While median EDSS scores trended higher for the AA than WA subsets, despite shorter disease duration, this difference was not significant. This is consistent with a previous report from the NYSMSC database using a smaller AA cohort. 14 In contrast, the differences in median MSSS between AA and WA cohorts were strikingly more pronounced, and significant.
It should also be noted that MSSS-based analysis may allow for identification of more risk factors of worse (or better) prognosis than when EDSS is used as a sole outcome variable. For example, in the 2
Figure 2
Differences in adjusted median Multiple Sclerosis Severity Scale (MSSS) for African American (AA) and white American (WA) men and women stratified by disease type and different ages at disease onset PP ϭ primary-progressive multiple sclerosis; RR ϭ relapsing-remitting multiple sclerosis; SP ϭ secondary-progressive multiple sclerosis. The reference group for each set of comparisons is WA women (baseline). The difference between adjusted median MSSS of WA men, AA men, AA women, and adjusted median MSSS of WA women is represented by bars. Each bar is shown with a vertical line that represents 95% confidence interval (CI). All differences in median MSSS are adjusted for disease duration, calendar year at the time of EDSS examination, use of disease-modifying therapy, family history of multiple sclerosis, and presence of coexisting autoimmune disease. Analyses are shown for the total sample and for patient subgroups stratified by disease type (RR, PP, and SP) and age at symptom onset (Ͻ26, 26 -45, and Ͼ45 years).
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